Abstract PR07: Novel phages targeting the intratumor-associated bacteria Fusobacterium nucleatum
Authors: Zelcbuch Lior , Yahav Sagit , Buchshtab Nufar , Kahan-Hanum Maya , Vainberg-Slutskin Ilya , Weiner Iddo , Golembo Myriam , Kredo-Russo Sharon , Zak Naomi , Gahali-Sass Inbar , Puttagunta Sailaja , Bassan Merav 
Published: December 2020

Abstract
Introduction: Recent studies demonstrate that bacterial species are present within the tumor microenvironment (Geller et al., 2017). The presence of F. nucleatum in tumors has been described to increase cancer cell proliferation, promote chemoresistance, and protect tumors against immune cell attack (Zhang et al., 2018). A higher abundance and prevalence of F. nucleatum has been associated with advanced tumor stage and poor prognosis in human colorectal carcinoma patients (Mima et al., 2016; Yan et al., 2017). Bacteriophages (“phages”) are viruses that specifically infect bacteria and play a critical role in regulating bacterial populations. Phages can be engineered to deliver therapeutic payloads (Schmidt, 2019). Reduction of intratumor F. nucleatum and targeted delivery of anticancer payloads to tumors using phages may offer novel approaches for localized cancer treatment. To date there are only a few reports identifying phages that target F. nucleatum (Zheng et al., 2019). Using an initially isolated phage, we have shown that these phages, administered intravenously, can reach tumor-associated F. nucleatum in vivo (Kahan-Hanum et al., 2019). The aim of the current study was to discover novel F. nucleatum-infecting phages that may serve to decrease intratumor F. nucleatum burden and/or deliver a localized payload for anticancer treatment.
Methods: For phage isolation, human saliva samples were screened on lawns of F. nucleatum strains, and natural phages were isolated from plaques. Phage sequences were analyzed following sequencing in Illumina using Nextera kits and genome assembly using SPAde genome assembler. To characterize infectivity, double layer plaque assays on different hosts were carried out. Phage editing was carried out by new molecular tools for F. nucleatum that were developed internally.
Results: Twelve novel phages were discovered, including phages against all 4 subspecies of F. nucleatum: animalis (n=2), vincentii (n=7), polymorphum (n=2), and nucleatum (n=1). Sequence analysis revealed that the phages differ greatly from one another and possess many unique features. Both temperate (lysogenic, n=4) and lytic (n=8) phages were isolated as determined by the presence of integrases required for lysogenic integration. Of the eight lytic phages, six share very little similarity with known phages or with each other. Moreover, two of the lytic phages are double-stranded lytic RNA phages, of which only eight have previously been reported. Editing of F. nucleatum-targeting phage by synthetic biology tools to introduce new sequences has already been carried out.
Conclusions: The newly discovered unique phages against F. nucleatum offer the first step in development of a novel therapy targeting intratumor bacteria. Reduction of intratumoral F. nucleatum bacterial burden and/or delivery of anticancer or immune-stimulating payloads to colonic tumors associated with F. nucleatum may offer novel treatment approaches for patients with colorectal cancer.
This abstract is also being presented as Poster B20.
Citation Format: Lior Zelcbuch, Sagit Yahav, Nufar Buchshtab, Maya Kahan-Hanum, Ilya Vainberg-Slutskin, Iddo Weiner, Myriam Golembo, Sharon Kredo-Russo, Naomi Zak, Inbar Gahali-Sass, Sailaja Puttagunta, Merav Bassan. Novel phages targeting the intratumor-associated bacteria Fusobacterium nucleatum [abstract]. In: Proceedings of the AACR Special Conference on the Microbiome, Viruses, and Cancer; 2020 Feb 21-24; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2020;80(8 Suppl):Abstract nr PR07.